Concepts (176)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Gallbladder Neoplasms | 7 | 2020 | 14 | 0.820 |
Why?
|
| Health Policy | 1 | 2024 | 191 | 0.750 |
Why?
|
| Troponin T | 1 | 2022 | 24 | 0.730 |
Why?
|
| Tuberculosis | 1 | 2024 | 308 | 0.660 |
Why?
|
| Exanthema | 1 | 2020 | 27 | 0.640 |
Why?
|
| Leg | 1 | 2020 | 87 | 0.640 |
Why?
|
| Hematologic Tests | 1 | 2020 | 16 | 0.630 |
Why?
|
| Hemolysis | 1 | 2020 | 41 | 0.630 |
Why?
|
| Health Services Accessibility | 1 | 2024 | 593 | 0.590 |
Why?
|
| Hemoglobins | 1 | 2020 | 136 | 0.580 |
Why?
|
| Proteomics | 6 | 2015 | 293 | 0.550 |
Why?
|
| Proteome | 4 | 2015 | 152 | 0.470 |
Why?
|
| Biomarkers, Tumor | 5 | 2016 | 524 | 0.430 |
Why?
|
| Bile | 1 | 2011 | 19 | 0.350 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2017 | 128 | 0.330 |
Why?
|
| Reference Values | 2 | 2022 | 327 | 0.330 |
Why?
|
| Antineoplastic Agents | 4 | 2017 | 644 | 0.270 |
Why?
|
| Mass Spectrometry | 5 | 2017 | 295 | 0.270 |
Why?
|
| India | 2 | 2024 | 164 | 0.250 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2020 | 583 | 0.250 |
Why?
|
| DNA Methylation | 3 | 2020 | 302 | 0.240 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2017 | 197 | 0.240 |
Why?
|
| Immunoassay | 2 | 2024 | 71 | 0.230 |
Why?
|
| Humans | 22 | 2024 | 65141 | 0.230 |
Why?
|
| Phosphotyrosine | 2 | 2015 | 25 | 0.230 |
Why?
|
| Triple Negative Breast Neoplasms | 2 | 2017 | 71 | 0.220 |
Why?
|
| Seroepidemiologic Studies | 1 | 2023 | 51 | 0.200 |
Why?
|
| Global Health | 1 | 2024 | 181 | 0.200 |
Why?
|
| Immunoglobulin M | 1 | 2023 | 116 | 0.200 |
Why?
|
| Interleukin-6 | 1 | 2024 | 323 | 0.190 |
Why?
|
| Biomarkers | 2 | 2022 | 1480 | 0.180 |
Why?
|
| Natriuretic Peptide, Brain | 1 | 2022 | 58 | 0.180 |
Why?
|
| Point-of-Care Systems | 1 | 2023 | 126 | 0.180 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2020 | 84 | 0.170 |
Why?
|
| Cell Line, Tumor | 8 | 2020 | 1566 | 0.170 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2015 | 261 | 0.170 |
Why?
|
| Immunoglobulin G | 1 | 2023 | 465 | 0.170 |
Why?
|
| Regression Analysis | 1 | 2022 | 497 | 0.170 |
Why?
|
| Reproducibility of Results | 3 | 2024 | 1698 | 0.170 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2020 | 19 | 0.160 |
Why?
|
| Frameshift Mutation | 1 | 2020 | 29 | 0.160 |
Why?
|
| Laboratory Proficiency Testing | 1 | 2020 | 2 | 0.160 |
Why?
|
| Peptide Fragments | 1 | 2022 | 417 | 0.160 |
Why?
|
| Bilirubin | 1 | 2020 | 19 | 0.160 |
Why?
|
| Automation, Laboratory | 1 | 2020 | 9 | 0.160 |
Why?
|
| Twist-Related Protein 1 | 1 | 2020 | 11 | 0.160 |
Why?
|
| Prognosis | 4 | 2017 | 1785 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2020 | 113 | 0.150 |
Why?
|
| Pandemics | 1 | 2023 | 675 | 0.140 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2018 | 62 | 0.140 |
Why?
|
| Peptide Chain Initiation, Translational | 1 | 2017 | 21 | 0.130 |
Why?
|
| 5' Untranslated Regions | 1 | 2017 | 28 | 0.130 |
Why?
|
| Open Reading Frames | 1 | 2017 | 84 | 0.130 |
Why?
|
| Mutation, Missense | 1 | 2018 | 190 | 0.130 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2018 | 205 | 0.130 |
Why?
|
| Benzoquinones | 1 | 2017 | 14 | 0.130 |
Why?
|
| Signal Transduction | 3 | 2020 | 3149 | 0.130 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2017 | 44 | 0.130 |
Why?
|
| Lactams, Macrocyclic | 1 | 2017 | 31 | 0.130 |
Why?
|
| Gene Expression Profiling | 2 | 2020 | 794 | 0.130 |
Why?
|
| Sensitivity and Specificity | 1 | 2020 | 1163 | 0.130 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2018 | 268 | 0.130 |
Why?
|
| Epigenesis, Genetic | 2 | 2020 | 407 | 0.120 |
Why?
|
| Gallstones | 1 | 2016 | 25 | 0.120 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2020 | 730 | 0.120 |
Why?
|
| Adenomatous Polyposis Coli Protein | 1 | 2016 | 10 | 0.120 |
Why?
|
| HSP90 Heat-Shock Proteins | 1 | 2017 | 63 | 0.120 |
Why?
|
| Drug Discovery | 1 | 2017 | 96 | 0.120 |
Why?
|
| Intramolecular Oxidoreductases | 1 | 2015 | 9 | 0.120 |
Why?
|
| Macrophage Migration-Inhibitory Factors | 1 | 2015 | 9 | 0.120 |
Why?
|
| Ribosomes | 1 | 2017 | 170 | 0.110 |
Why?
|
| Nuclear Proteins | 1 | 2020 | 790 | 0.110 |
Why?
|
| Ephrin-A2 | 1 | 2015 | 2 | 0.110 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Kinase | 1 | 2015 | 2 | 0.110 |
Why?
|
| Chromatography, Liquid | 2 | 2014 | 117 | 0.110 |
Why?
|
| Cell Proliferation | 5 | 2017 | 1036 | 0.110 |
Why?
|
| Genome, Human | 1 | 2016 | 237 | 0.110 |
Why?
|
| Saposins | 1 | 2014 | 1 | 0.110 |
Why?
|
| Stomach Neoplasms | 1 | 2015 | 81 | 0.100 |
Why?
|
| Gallbladder | 1 | 2014 | 40 | 0.100 |
Why?
|
| DNA-Binding Proteins | 1 | 2020 | 1225 | 0.100 |
Why?
|
| Immunity, Innate | 1 | 2020 | 822 | 0.100 |
Why?
|
| Promoter Regions, Genetic | 1 | 2016 | 687 | 0.100 |
Why?
|
| Esophageal Neoplasms | 1 | 2015 | 94 | 0.100 |
Why?
|
| Muscle Proteins | 1 | 2014 | 117 | 0.100 |
Why?
|
| Microfilament Proteins | 1 | 2014 | 115 | 0.100 |
Why?
|
| Transcription Factors | 1 | 2020 | 1554 | 0.090 |
Why?
|
| Xenograft Model Antitumor Assays | 3 | 2017 | 203 | 0.090 |
Why?
|
| Head and Neck Neoplasms | 1 | 2013 | 166 | 0.090 |
Why?
|
| Lung Neoplasms | 1 | 2018 | 704 | 0.090 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 185 | 0.090 |
Why?
|
| Adenocarcinoma | 1 | 2015 | 366 | 0.090 |
Why?
|
| Male | 5 | 2024 | 31055 | 0.080 |
Why?
|
| Adolescent | 1 | 2020 | 6306 | 0.080 |
Why?
|
| Neoplasms | 1 | 2020 | 1367 | 0.070 |
Why?
|
| Phosphorylation | 3 | 2017 | 962 | 0.070 |
Why?
|
| Female | 7 | 2024 | 34030 | 0.060 |
Why?
|
| Middle Aged | 4 | 2024 | 18273 | 0.060 |
Why?
|
| HEK293 Cells | 2 | 2018 | 615 | 0.060 |
Why?
|
| Mice, Transgenic | 2 | 2020 | 1290 | 0.060 |
Why?
|
| Tissue Array Analysis | 2 | 2016 | 39 | 0.060 |
Why?
|
| Molecular Targeted Therapy | 2 | 2015 | 128 | 0.050 |
Why?
|
| Cell Survival | 2 | 2017 | 587 | 0.050 |
Why?
|
| Enzyme Activation | 2 | 2015 | 391 | 0.050 |
Why?
|
| Cell Movement | 2 | 2017 | 480 | 0.050 |
Why?
|
| Mice | 4 | 2020 | 11114 | 0.050 |
Why?
|
| Disease Progression | 2 | 2020 | 1219 | 0.050 |
Why?
|
| Adult | 3 | 2024 | 17358 | 0.050 |
Why?
|
| Follow-Up Studies | 2 | 2020 | 2484 | 0.050 |
Why?
|
| Gene Expression | 2 | 2017 | 852 | 0.050 |
Why?
|
| Animals | 5 | 2020 | 21333 | 0.050 |
Why?
|
| Immunohistochemistry | 2 | 2015 | 896 | 0.050 |
Why?
|
| Macrophages | 2 | 2020 | 1037 | 0.050 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2024 | 250 | 0.040 |
Why?
|
| Gene Silencing | 2 | 2015 | 433 | 0.040 |
Why?
|
| Chile | 1 | 2020 | 14 | 0.040 |
Why?
|
| Kelch-Like ECH-Associated Protein 1 | 1 | 2020 | 11 | 0.040 |
Why?
|
| Desmin | 1 | 2020 | 8 | 0.040 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2020 | 33 | 0.040 |
Why?
|
| Cancer Vaccines | 1 | 2020 | 51 | 0.040 |
Why?
|
| beta Catenin | 1 | 2020 | 99 | 0.040 |
Why?
|
| Principal Component Analysis | 1 | 2020 | 65 | 0.040 |
Why?
|
| Interleukin-13 | 1 | 2020 | 37 | 0.040 |
Why?
|
| Chemokine CCL2 | 1 | 2020 | 61 | 0.040 |
Why?
|
| RAW 264.7 Cells | 1 | 2020 | 50 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2020 | 168 | 0.040 |
Why?
|
| Wnt Signaling Pathway | 1 | 2020 | 86 | 0.040 |
Why?
|
| Republic of Korea | 1 | 2020 | 207 | 0.040 |
Why?
|
| Disease Models, Animal | 2 | 2017 | 2293 | 0.040 |
Why?
|
| Fibrosis | 1 | 2020 | 172 | 0.040 |
Why?
|
| Neoplasm Metastasis | 1 | 2020 | 222 | 0.040 |
Why?
|
| Down-Regulation | 1 | 2020 | 324 | 0.040 |
Why?
|
| Hexosamines | 1 | 2018 | 4 | 0.040 |
Why?
|
| Acylation | 1 | 2018 | 16 | 0.040 |
Why?
|
| A549 Cells | 1 | 2018 | 39 | 0.040 |
Why?
|
| Sequence Analysis, RNA | 1 | 2020 | 180 | 0.040 |
Why?
|
| Tumor Microenvironment | 1 | 2020 | 182 | 0.040 |
Why?
|
| Mice, Nude | 1 | 2018 | 287 | 0.030 |
Why?
|
| Amino Acid Substitution | 1 | 2018 | 237 | 0.030 |
Why?
|
| Human Umbilical Vein Endothelial Cells | 1 | 2017 | 45 | 0.030 |
Why?
|
| Genomics | 1 | 2020 | 384 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2017 | 47 | 0.030 |
Why?
|
| Protein Domains | 1 | 2017 | 153 | 0.030 |
Why?
|
| Small Molecule Libraries | 1 | 2017 | 57 | 0.030 |
Why?
|
| Neoplasm Grading | 1 | 2016 | 94 | 0.030 |
Why?
|
| Transcription Initiation Site | 1 | 2016 | 47 | 0.030 |
Why?
|
| High-Throughput Screening Assays | 1 | 2017 | 79 | 0.030 |
Why?
|
| Gene Knockdown Techniques | 1 | 2017 | 203 | 0.030 |
Why?
|
| Epigenomics | 1 | 2016 | 62 | 0.030 |
Why?
|
| Fourier Analysis | 1 | 2015 | 31 | 0.030 |
Why?
|
| Protein Interaction Maps | 1 | 2015 | 35 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2015 | 75 | 0.030 |
Why?
|
| Glucose | 1 | 2018 | 476 | 0.030 |
Why?
|
| CpG Islands | 1 | 2016 | 219 | 0.030 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 1 | 2015 | 61 | 0.030 |
Why?
|
| Exons | 1 | 2016 | 208 | 0.030 |
Why?
|
| Esophagus | 1 | 2015 | 47 | 0.030 |
Why?
|
| Survival Rate | 1 | 2017 | 844 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2015 | 415 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2015 | 518 | 0.030 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2015 | 83 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 526 | 0.030 |
Why?
|
| Neoplasm Proteins | 1 | 2015 | 285 | 0.030 |
Why?
|
| Transfection | 1 | 2015 | 701 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 1 | 2015 | 343 | 0.030 |
Why?
|
| Secretory Pathway | 1 | 2013 | 6 | 0.020 |
Why?
|
| Tandem Mass Spectrometry | 1 | 2014 | 137 | 0.020 |
Why?
|
| Neck | 1 | 2013 | 46 | 0.020 |
Why?
|
| Head | 1 | 2013 | 57 | 0.020 |
Why?
|
| Early Detection of Cancer | 1 | 2015 | 325 | 0.020 |
Why?
|
| RNA Interference | 1 | 2015 | 643 | 0.020 |
Why?
|
| Apoptosis | 1 | 2017 | 1100 | 0.020 |
Why?
|
| Phenotype | 1 | 2015 | 1232 | 0.020 |
Why?
|
| Cell Line | 1 | 2015 | 2023 | 0.020 |
Why?
|
| Time Factors | 1 | 2015 | 3762 | 0.020 |
Why?
|
| Aged | 1 | 2024 | 14963 | 0.020 |
Why?
|